Credit option volumes grew dramatically in 2005, and we expect a continued broadening of the account base in 2006 as investors focus on the convexity profile of their portfolios.
Gilead has been extremely disingenuous. Gilead`s access program is a lie.
It seems like the drug industries are saying, `The older drugs are available and they`re cheap so we`ve done our thing.